Anthos, Novartis

Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement of regulatory and sales milestones. The transaction, which could reach $3.1 billion in total value, is expected to close in the early part of 2025.
Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.
Novartis agrees to acquire Anthos for up to $3.1 billion
Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, the companies said on Tuesday.
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its cardiovascular pipeline.
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease.
Novartis buys Blackstone's Anthos for up to $3.1 billion
By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.
Novartis Strikes Up to $3.1 Billion Deal to Buy Anthos Therapeutics
Novartis (NVS) on Tuesday agreed to acquire biopharmaceutical firm Anthos Therapeutics in a deal worth up to $3.1 billion, as the Swiss pharmaceutical giant looks to boost its cardiovascular portfolio.
Novartis: Just What The Doctor Ordered
Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...
ETF Daily News14h
Novartis (NYSE:NVS) Earns “Neutral” Rating from UBS Group
Novartis (NYSE:NVS – Get Free Report)‘s stock had its “neutral” rating reissued by investment analysts at UBS Group in a research report issued to clients and investors on Thursday, MarketBeat ...
BioPharma Dive3d
Novartis pays $925M to reel in a startup it helped launch
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Fierce Biotech4d
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
Novartis’ Ianalumab granted FDA orphan designation
Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the ...
Medical Marketing & Media4d
Novartis’ chief marketing officer on the drugmaker’s Super Bowl ad debut
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
Novartis to pay $3.1B for Cambridge biotech led by former Karuna CEO
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...
cnbctv1821h
Future Female Forward | Diverse workforce is a cornerstone of Novartis culture, says Anjali Rao
At Novartis India, the focus on gender equality and the promotion of women in leadership roles is not just a corporate initiative—it's a commitment ingrained in the organisation's culture. Speaking to ...